Developer docs
API playgroundTry for free, no card

Search company profiles

Erasca

Full company profile

uuid0000ckp

Namestring
Erasca
Legal namestring
Erasca, Inc.
Websiteurl
erasca.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company headquartered in San Diego, California, founded in July 2018 by Jonathan E. Lim, M.D. and Kevan Shokat, Ph.D. The company is developing a modality-agnostic pipeline of 11 distinct drug programs targeting the RAS/MAPK signaling cascade — implicated in roughly one-third of all solid tumors and approximately 5.5 million new cancer diagnoses annually worldwide. Erasca organizes its pipeline around three therapeutic strategies: MAPKlamp (clamping oncogenic drivers between upstream SHP2 and downstream ERK inhibitors, e.g., ERAS-601 and ERAS-007), direct RAS targeting (lead assets ERAS-0015, an oral pan-RAS molecular glue forming a RAS-Cyclophilin A complex with claimed 5- to 10-fold potency advantage over RMC-6236; and ERAS-4001, a pan-KRAS inhibitor locking KRAS in its inactive GDP-bound state), and escape-route targeting (ERAS-12 EGFR bispecific, ERAS-801, ERAS-9 SOS1, ERAS-5 ULK, ERAS-11 MYC). Lead assets are being evaluated in two Phase 1 trials: AURORAS-1 (ERAS-0015, RAS-mutant solid tumors) and BOREALIS-1 (ERAS-4001, KRAS-mutant solid tumors), with combinations running alongside panitumumab, Merck's KEYTRUDA, Tango's vopimetostat, and Verastem's VS-7375.

The company has no commercial products and generates no product revenue; operations are funded by equity issuance (approximately $587.8 million raised post-IPO across four rounds, including an upsized $258.8M public offering in January 2026). FY2025 net loss narrowed to $124.5 million from $161.7 million in FY2024, with $341.8M in cash at year-end 2025 and a pro forma $434M supporting runway into H2 2028. Go-to-market today is centered on global clinical trial site recruitment, Key Opinion Leader engagement, and clinical combination collaborations with strategic pharma partners that supply combination agents at no cost; future commercialization will target oncology prescribers and patients across PDAC, NSCLC, and CRC. The company wholly owns Erasca Ventures (an equity investment vehicle) and the Erasca Foundation (a 501(c)(3) established at IPO funded with 1,093,557 shares). Erasca faces material 2026 headwinds: a Grade 5 patient death in the AURORAS-1 trial, an active patent infringement and trade-secret dispute with Revolution Medicines regarding ERAS-0015, and multiple securities class action lawsuits alleging misleading preclinical disclosures.

Short descriptiontext

Erasca is a clinical-stage precision oncology company developing a modality-agnostic pipeline of 11 drug programs targeting the RAS/MAPK pathway for patients with RAS-mutant solid tumors, including pancreatic, lung, and colorectal cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology drugs, RAS/MAPK pathway therapy, clinical-stage biopharmaceutical, oncology drug pipeline, targeted cancer therapeutics
Industry2 codes
PRIMARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAGACAK
Clinical Trial Pharmacy & IMP Management at Site
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Precision Oncology Drug Development
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1No commercial product revenue
TypeSubscription Recurring
Description

Clinical-stage precision oncology company with no commercial products approved; generates no product revenue. Operations funded by capital raised through public equity offerings and private placements. Net loss of $124.5 million for full year 2025, down from $161.7 million in 2024.

biospace.com
2Public equity financing
TypeLicensing Royalties
Description

Raised approximately $258.8 million through January 2026 upsized public offering of 25,875,000 shares at $10.00 per share; earlier raised approximately $184 million (May 2024 at $1.85/share), $45 million (March 2024 at $2.06/share), and approximately $100 million (December 2022 at $6.50/share)

biospace.com
3Licensed pan-RAS molecular glue franchise (ERAS-0015)
TypeLicensing Royalties
Description

Holds worldwide license to ERAS-0015 from Joyo Pharmatech Co., Ltd. (expanded in March 2026 to include China, Hong Kong, and Macau); potential future royalty/licensing revenue streams tied to commercialization

in.investing.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1No commercial pricing available - clinical-stage only
ModelOther
Notes

Quote-based / Not publicly disclosed

erasca.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Erasca Ventures
Description

Wholly-owned subsidiary making equity investments in early-stage biotechnology companies aligned with Erasca's mission and strategy.

erasca.com
+1 more record
Core offering1 text field

Erasca is a clinical-stage precision oncology biopharmaceutical company developing a modality-agnostic pipeline of 11 investigational drug programs (small molecules, large molecules, protein degraders) that comprehensively target the RAS/MAPK signaling cascade across three strategies: MAPKlamp upstream/downstream node inhibition, direct RAS targeting, and escape-route targeting. Lead clinical assets ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor) are advancing through Phase 1 trials in RAS-mutant solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ERAS-0015 demonstrated 5- to 10-fold greater in vitro and in vivo potency versus comparator pan-RAS molecular glue in preclinical side-by-side comparisons, with 5 to 21 times higher binding affinity and potency versus competitor compound RMC-6236
+3 more records
Product overview1 text field

Erasca is a clinical-stage precision oncology company offering a modality-agnostic pipeline of investigational drug programs (rather than a single unified product or software platform) targeting the RAS/MAPK pathway across three therapeutic strategies: (1) targeting upstream and downstream MAPK nodes via the MAPKlamp approach with programs such as ERAS-601 (SHP2) and ERAS-007 (ERK); (2) directly targeting RAS with the lead programs ERAS-0015 (a pan-RAS molecular glue) and ERAS-4001 (a pan-KRAS inhibitor), plus discovery-stage ERAS-1 (KRAS G12C) and ERAS-4 (KRAS G12D); and (3) targeting escape routes with programs such as ERAS-12 (EGFR D2/D3 bispecific antibody), ERAS-801 (EGFR), ERAS-9 (SOS1), ERAS-5 (ULK), and ERAS-11 (MYC). The lead clinical assets ERAS-0015 (AURORAS-1 trial) and ERAS-4001 (BOREALIS-1 trial) are being evaluated as monotherapies and in combinations with partners such as Merck (KEYTRUDA), Verastem Oncology (VS-7375), Tango Therapeutics (vopimetostat), and panitumumab.

Product and service11 records
1ERAS-0015
CategoryLead clinical-stage drug candidate (pan-RAS molecular glue)
Description

ERAS-0015 is Erasca's lead clinical-stage drug candidate, an oral small-molecule pan-RAS molecular glue that forms a RAS-Cyclophilin A protein complex to potently and selectively bind oncogenic RAS alterations (e.g., G12X, G13X +/- Q61X) and block RAS-mediated signaling; evaluated in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors.

2ERAS-4001
CategoryClinical-stage drug candidate (pan-KRAS inhibitor)
Description

ERAS-4001 is a clinical-stage potent and selective pan-KRAS inhibitor that locks KRAS in the inactive GDP-bound state to provide an improved therapeutic window over RAS inhibitors and prevent KRAS wildtype-mediated resistance; evaluated in the BOREALIS-1 Phase 1 trial.

3ERAS-601
CategoryMAPKlamp program (upstream MAPK node inhibitor)
Description

ERAS-601 is an SHP2 inhibitor targeting the upstream MAPK pathway node as part of Erasca's MAPKlamp strategy to clamp oncogenic drivers (RAS, RAF, MEK alterations) trapped between upstream and downstream nodes.

4ERAS-007
CategoryMAPKlamp program (downstream MAPK node inhibitor)
Description

ERAS-007 is an ERK inhibitor targeting the downstream MAPK pathway node as part of Erasca's MAPKlamp strategy; has been evaluated in the HERKULES-3 Phase 1b/2 clinical trial in combination with various agents in colorectal cancer patients.

5ERAS-801
CategoryEscape route targeting program (EGFR inhibitor)
Description

ERAS-801 is an EGFR inhibitor representing a key escape route for MAPK signaling that has been evaluated in the THUNDERBBOLT-1 Phase 1 clinical trial in patients with recurrent glioblastoma (GBM).

6ERAS-12
CategoryDiscovery-stage drug candidate (EGFR D2/D3 bispecific antibody)
Description

ERAS-12 is a discovery-stage bispecific antibody program targeting EGFR domains D2 and D3, designed to inhibit both the inactive and active conformations of wildtype EGFR in EGFR- and RAS/MAPK-altered tumors.

7ERAS-1
CategoryDiscovery program (CNS-penetrant KRAS G12C inhibitor)
Description

ERAS-1 is a CNS-penetrant inhibitor of KRAS G12C, the only RAS isoform and mutation more commonly present in the inactive RAS-GDP state, developed using structure-based drug design.

8ERAS-4
CategoryDiscovery program (KRAS G12D inhibitor)
Description

ERAS-4 is a proprietary compound targeting KRAS G12D, the most prevalent KRAS mutation found more commonly in the active RAS-GTP state.

9ERAS-5
CategoryDiscovery program (ULK autophagy inhibitor)
Description

ERAS-5 is an inhibitor targeting ULK, a key regulator of autophagy, intended to shut down an escape route for RAS-driven metabolically active tumors such as pancreatic ductal adenocarcinoma, for use in combination with RAS-targeting agents.

10ERAS-9
CategoryDiscovery program (SOS1 inhibitor)
Description

ERAS-9 is a SOS1 inhibitor targeting a guanine nucleotide exchange factor that enables RAS to cycle from the inactive GDP state to the active GTP state, addressing escape routes that impact the RAS/MAPK pathway.

11ERAS-11
CategoryDiscovery program (MYC transcriptional target)
Description

ERAS-11 targets MYC, a transcription factor and oncogene that is overexpressed in the majority of cancers and serves as a key enabler of RAS/MAPK pathway signaling at the transcriptional level.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Intent to collaborate to evaluate Verastem's VS-7375 (an investigational oral KRAS G12D inhibitor) in combination with Erasca's ERAS-0015 pan-RAS molecular glue in advanced KRAS G12D-mutant solid tumors, pending execution of a definitive agreement.

2The Lustgarten Foundation
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-15
Description

Erasca was honored at the Lustgarten Foundation's annual Inspiring Hope Gala on June 3, 2026 alongside Elizabeth Jaffee and Eileen M. O'Reilly for contributions to advancing pancreatic cancer research. The Foundation is the world's largest private funder of pancreatic cancer research and has invested $333 million in 386 research projects over nearly 28 years.

prnewswire.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-11
Description

Clinical trial collaboration and supply agreement to evaluate Erasca's pan-RAS molecular glue ERAS-0015 in combination with Merck's KEYTRUDA (pembrolizumab) in the AURORAS-1 proof-of-concept study for patients with RAS-mutant solid tumors. Erasca sponsors the study while Merck supplies pembrolizumab at no cost. Targets an annual global patient population of approximately 2.7 million diagnosed with RASm tumors.

Strategic tierUnclearTypeOthersAnnounced on2026-04-28
Description

Not a partnership in the traditional sense; Revolution Medicines sent a legal demand letter to Erasca on April 27, 2026 alleging that Erasca's ERAS-0015 pancreatic cancer drug candidate infringes on patent protections for Revolution's drug daraxonrasib (U.S. Patent No. 12,409,225) and that Erasca improperly compared preclinical data. Erasca disclosed the letter in an SEC filing and stated it plans to fight the claims vigorously. The dispute has resulted in multiple securities class action lawsuits against Erasca.

5Joyo Pharmatech Co., Ltd.
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-10
Description

License agreement for ERAS-0015 pan-RAS molecular glue. In March 2026, Erasca exercised option to expand license to include China, Hong Kong, and Macau, securing worldwide rights to ERAS-0015 and enabling unified global development and commercialization strategy with full clinical data control.

in.investing.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

Clinical trial collaboration and supply agreement to evaluate Erasca's pan-RAS molecular glue ERAS-0015 in combination with Tango's PRMT5 inhibitor vopimetostat in a Phase 1/2 trial for patients with MTAP-deleted pancreatic cancer or MTAP-deleted RAS-mutant NSCLC. Tango sponsors the trial while Erasca supplies ERAS-0015 at no cost under a mutually non-exclusive agreement.

Strategic tierMinorTypeOthersAnnounced on2026-03-05
Description

Referenced as a partner of Tango Therapeutics running a parallel combination trial with vopimetostat (PRMT5 inhibitor) + daraxonrasib (Revolution Medicines' RAS inhibitor); comparable to Erasca's combination trial with vopimetostat + ERAS-0015.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Verastem is developing VS-7375, an oral KRAS G12D inhibitor intended for combination with Erasca's ERAS-0015. Verastem is a focused emerging player in RAS-mutant oncology with overlapping indications in pancreatic and other RAS-mutant tumors.

TypeBroad incumbent
Description

Amgen developed and commercializes LUMAKRAS (sotorasib), the first FDA-approved KRAS G12C inhibitor. As a broad incumbent in RAS-targeted oncology, Amgen is a major competitor in commercial positioning and combination strategy.

TypeDirect peer
Description

Revolution Medicines is Erasca's closest direct competitor, developing RMC-6236 (a pan-RAS(ON) inhibitor) and daraxonrasib (KRAS G12D), and is the comparator in Erasca's own preclinical studies. RevMed and Erasca are currently engaged in active IP/trade-secret litigation over ERAS-0015.

TypeEmerging player
Description

Tango Therapeutics is both an Erasca combination partner (vopimetostat + ERAS-0015) and an emerging precision oncology peer with synthetic-lethality programs including PRMT5 inhibition. Tangentially competing in the same patient populations via combination strategies.

TypeDirect peer
Description

Mirati developed KRAZATI (adagrasib), a KRAS G12C inhibitor, making it a direct KRAS competitor to Erasca's pan-RAS and KRAS programs. Acquired by Bristol-Myers Squibb in 2024, Mirati's portfolio provides a benchmark for RAS-targeting clinical and commercial execution.

6Bristol-Myers Squibb
TypeBroad incumbent
Description

BMS owns KRAZATI (via Mirati acquisition) and has deep oncology commercial reach, positioning it as a broad incumbent competing with Erasca's RAS/MAPK pipeline. BMS is also a potential strategic acquirer for pan-RAS assets in the same competitive space.

TypeDirect peer
Description

Black Diamond is a clinical-stage precision oncology company developing a pipeline of targeted therapies against oncogenic driver mutations. Comparable in size, modality mix (small molecules), and clinical-stage risk profile to Erasca.

TypeEmerging player
Description

PMV Pharma is a clinical-stage precision oncology company developing small molecules that reactivate mutant p53 (e.g., PC14586). Comparable as a similarly-sized clinical-stage precision oncology company with a focused mechanism-driven approach.

TypeDirect peer
Description

Relay Therapeutics is a clinical-stage precision oncology company developing RLY-4008 (lirafugratinib) and other targeted therapies with a motion-based drug discovery platform. Comparable as a similarly-sized clinical-stage precision oncology peer with pipeline depth and similar burn profile.

TypeEmerging player
Description

Foghorn Therapeutics is a clinical-stage precision oncology company targeting the chromatin regulatory system, with a pipeline of small molecules. Comparable as a precision oncology peer with multiple programs in development against oncology targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Erasca

Precision Oncology Drug Developmenterasca.com

Erasca is a clinical-stage precision oncology company developing a modality-agnostic pipeline of 11 drug programs targeting the RAS/MAPK pathway for patients with RAS-mutant solid tumors, including pancreatic, lung, and colorectal cancers.

What Erasca does

Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company headquartered in San Diego, California, founded in July 2018 by Jonathan E. Lim, M.D. and Kevan Shokat, Ph.D. The company is developing a modality-agnostic pipeline of 11 distinct drug programs targeting the RAS/MAPK signaling cascade — implicated in roughly one-third of all solid tumors and approximately 5.5 million new cancer diagnoses annually worldwide. Erasca organizes its pipeline around three therapeutic strategies: MAPKlamp (clamping oncogenic drivers between upstream SHP2 and downstream ERK inhibitors, e.g., ERAS-601 and ERAS-007), direct RAS targeting (lead assets ERAS-0015, an oral pan-RAS molecular glue forming a RAS-Cyclophilin A complex with claimed 5- to 10-fold potency advantage over RMC-6236; and ERAS-4001, a pan-KRAS inhibitor locking KRAS in its inactive GDP-bound state), and escape-route targeting (ERAS-12 EGFR bispecific, ERAS-801, ERAS-9 SOS1, ERAS-5 ULK, ERAS-11 MYC). Lead assets are being evaluated in two Phase 1 trials: AURORAS-1 (ERAS-0015, RAS-mutant solid tumors) and BOREALIS-1 (ERAS-4001, KRAS-mutant solid tumors), with combinations running alongside panitumumab, Merck's KEYTRUDA, Tango's vopimetostat, and Verastem's VS-7375.

The company has no commercial products and generates no product revenue; operations are funded by equity issuance (approximately $587.8 million raised post-IPO across four rounds, including an upsized $258.8M public offering in January 2026). FY2025 net loss narrowed to $124.5 million from $161.7 million in FY2024, with $341.8M in cash at year-end 2025 and a pro forma $434M supporting runway into H2 2028. Go-to-market today is centered on global clinical trial site recruitment, Key Opinion Leader engagement, and clinical combination collaborations with strategic pharma partners that supply combination agents at no cost; future commercialization will target oncology prescribers and patients across PDAC, NSCLC, and CRC. The company wholly owns Erasca Ventures (an equity investment vehicle) and the Erasca Foundation (a 501(c)(3) established at IPO funded with 1,093,557 shares). Erasca faces material 2026 headwinds: a Grade 5 patient death in the AURORAS-1 trial, an active patent infringement and trade-secret dispute with Revolution Medicines regarding ERAS-0015, and multiple securities class action lawsuits alleging misleading preclinical disclosures.

Erasca firmographics

Firmographics
Name
Erasca
Legal name
Erasca, Inc.
Website
https://erasca.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Erasca is a clinical-stage precision oncology company developing a modality-agnostic pipeline of 11 drug programs targeting the RAS/MAPK pathway for patients with RAS-mutant solid tumors, including pancreatic, lung, and colorectal cancers.
Ownership category
akta.pro rank

Erasca industry classification

Industry
Product category
Precision Oncology Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAGACAK
Clinical Trial Pharmacy & IMP Management at Site

Keywords

  • Precision oncology drugs
  • RAS/MAPK pathway therapy
  • Clinical-stage biopharmaceutical
  • Oncology drug pipeline
  • Targeted cancer therapeutics

Where Erasca is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Erasca business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. No commercial product revenue: Clinical-stage precision oncology company with no commercial products approved; generates no product revenue. Operations funded by capital raised through public equity offerings and private placements. Net loss of $124.5 million for full year 2025, down from $161.7 million in 2024.
  2. Public equity financing: Raised approximately $258.8 million through January 2026 upsized public offering of 25,875,000 shares at $10.00 per share; earlier raised approximately $184 million (May 2024 at $1.85/share), $45 million (March 2024 at $2.06/share), and approximately $100 million (December 2022 at $6.50/share)
  3. Licensed pan-RAS molecular glue franchise (ERAS-0015): Holds worldwide license to ERAS-0015 from Joyo Pharmatech Co., Ltd. (expanded in March 2026 to include China, Hong Kong, and Macau); potential future royalty/licensing revenue streams tied to commercialization

Pricing tiers

ModelBillingPrice
Other—No commercial pricing available - clinical-stage only

Go-to-market motion4 records

Distribution channels5 records

Marketing channels9 records

Erasca product offering

Product offering

Core offering

Erasca is a clinical-stage precision oncology biopharmaceutical company developing a modality-agnostic pipeline of 11 investigational drug programs (small molecules, large molecules, protein degraders) that comprehensively target the RAS/MAPK signaling cascade across three strategies: MAPKlamp upstream/downstream node inhibition, direct RAS targeting, and escape-route targeting. Lead clinical assets ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor) are advancing through Phase 1 trials in RAS-mutant solid tumors.

Product overview

Erasca is a clinical-stage precision oncology company offering a modality-agnostic pipeline of investigational drug programs (rather than a single unified product or software platform) targeting the RAS/MAPK pathway across three therapeutic strategies: (1) targeting upstream and downstream MAPK nodes via the MAPKlamp approach with programs such as ERAS-601 (SHP2) and ERAS-007 (ERK); (2) directly targeting RAS with the lead programs ERAS-0015 (a pan-RAS molecular glue) and ERAS-4001 (a pan-KRAS inhibitor), plus discovery-stage ERAS-1 (KRAS G12C) and ERAS-4 (KRAS G12D); and (3) targeting escape routes with programs such as ERAS-12 (EGFR D2/D3 bispecific antibody), ERAS-801 (EGFR), ERAS-9 (SOS1), ERAS-5 (ULK), and ERAS-11 (MYC). The lead clinical assets ERAS-0015 (AURORAS-1 trial) and ERAS-4001 (BOREALIS-1 trial) are being evaluated as monotherapies and in combinations with partners such as Merck (KEYTRUDA), Verastem Oncology (VS-7375), Tango Therapeutics (vopimetostat), and panitumumab.

Differentiator

Problem solved

Functional benefit

Brands

  • Erasca Ventures: Wholly-owned subsidiary making equity investments in early-stage biotechnology companies aligned with Erasca's mission and strategy.
  • Erasca Foundation

Products and services

  • ERAS-0015 ERAS-0015 is Erasca's lead clinical-stage drug candidate, an oral small-molecule pan-RAS molecular glue that forms a RAS-Cyclophilin A protein complex to potently and selectively bind oncogenic RAS alterations (e.g., G12X, G13X +/- Q61X) and block RAS-mediated signaling; evaluated in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors.
  • ERAS-4001 ERAS-4001 is a clinical-stage potent and selective pan-KRAS inhibitor that locks KRAS in the inactive GDP-bound state to provide an improved therapeutic window over RAS inhibitors and prevent KRAS wildtype-mediated resistance; evaluated in the BOREALIS-1 Phase 1 trial.
  • ERAS-601 ERAS-601 is an SHP2 inhibitor targeting the upstream MAPK pathway node as part of Erasca's MAPKlamp strategy to clamp oncogenic drivers (RAS, RAF, MEK alterations) trapped between upstream and downstream nodes.
  • ERAS-007 ERAS-007 is an ERK inhibitor targeting the downstream MAPK pathway node as part of Erasca's MAPKlamp strategy; has been evaluated in the HERKULES-3 Phase 1b/2 clinical trial in combination with various agents in colorectal cancer patients.
  • ERAS-801 ERAS-801 is an EGFR inhibitor representing a key escape route for MAPK signaling that has been evaluated in the THUNDERBBOLT-1 Phase 1 clinical trial in patients with recurrent glioblastoma (GBM).
  • ERAS-12 ERAS-12 is a discovery-stage bispecific antibody program targeting EGFR domains D2 and D3, designed to inhibit both the inactive and active conformations of wildtype EGFR in EGFR- and RAS/MAPK-altered tumors.
  • ERAS-1 ERAS-1 is a CNS-penetrant inhibitor of KRAS G12C, the only RAS isoform and mutation more commonly present in the inactive RAS-GDP state, developed using structure-based drug design.
  • ERAS-4 ERAS-4 is a proprietary compound targeting KRAS G12D, the most prevalent KRAS mutation found more commonly in the active RAS-GTP state.
  • ERAS-5 ERAS-5 is an inhibitor targeting ULK, a key regulator of autophagy, intended to shut down an escape route for RAS-driven metabolically active tumors such as pancreatic ductal adenocarcinoma, for use in combination with RAS-targeting agents.
  • ERAS-9 ERAS-9 is a SOS1 inhibitor targeting a guanine nucleotide exchange factor that enables RAS to cycle from the inactive GDP state to the active GTP state, addressing escape routes that impact the RAS/MAPK pathway.
  • ERAS-11 ERAS-11 targets MYC, a transcription factor and oncogene that is overexpressed in the majority of cancers and serves as a key enabler of RAS/MAPK pathway signaling at the transcriptional level.

Quantifiable outcome

  • ERAS-0015 demonstrated 5- to 10-fold greater in vitro and in vivo potency versus comparator pan-RAS molecular glue in preclinical side-by-side comparisons, with 5 to 21 times higher binding affinity and potency versus competitor compound RMC-6236
  • +3 more outcomes

Companies that use Erasca

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Erasca technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Erasca partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, minor, flagship and unclear.

  • Verastem OncologycoreStrategic or Co-development Partner · 23 June 2026Intent to collaborate to evaluate Verastem's VS-7375 (an investigational oral KRAS G12D inhibitor) in combination with Erasca's ERAS-0015 pan-RAS molecular glue in advanced KRAS G12D-mutant solid tumors, pending execution of a definitive agreement.
  • The Lustgarten FoundationminorGTM or Marketing Partner · 15 June 2026Erasca was honored at the Lustgarten Foundation's annual Inspiring Hope Gala on June 3, 2026 alongside Elizabeth Jaffee and Eileen M. O'Reilly for contributions to advancing pancreatic cancer research. The Foundation is the world's largest private funder of pancreatic cancer research and has invested $333 million in 386 research projects over nearly 28 years.
  • MerckflagshipStrategic or Co-development Partner · 11 May 2026Clinical trial collaboration and supply agreement to evaluate Erasca's pan-RAS molecular glue ERAS-0015 in combination with Merck's KEYTRUDA (pembrolizumab) in the AURORAS-1 proof-of-concept study for patients with RAS-mutant solid tumors. Erasca sponsors the study while Merck supplies pembrolizumab at no cost. Targets an annual global patient population of approximately 2.7 million diagnosed with RASm tumors.
  • Revolution Medicines, Inc.unclearOthers · 28 April 2026Not a partnership in the traditional sense; Revolution Medicines sent a legal demand letter to Erasca on April 27, 2026 alleging that Erasca's ERAS-0015 pancreatic cancer drug candidate infringes on patent protections for Revolution's drug daraxonrasib (U.S. Patent No. 12,409,225) and that Erasca improperly compared preclinical data. Erasca disclosed the letter in an SEC filing and stated it plans to fight the claims vigorously. The dispute has resulted in multiple securities class action lawsuits against Erasca.
  • Joyo Pharmatech Co., Ltd.flagshipOEM/ Whitelabel/ Licensing Partner · 10 March 2026License agreement for ERAS-0015 pan-RAS molecular glue. In March 2026, Erasca exercised option to expand license to include China, Hong Kong, and Macau, securing worldwide rights to ERAS-0015 and enabling unified global development and commercialization strategy with full clinical data control.
  • Tango TherapeuticscoreStrategic or Co-development Partner · 5 March 2026Clinical trial collaboration and supply agreement to evaluate Erasca's pan-RAS molecular glue ERAS-0015 in combination with Tango's PRMT5 inhibitor vopimetostat in a Phase 1/2 trial for patients with MTAP-deleted pancreatic cancer or MTAP-deleted RAS-mutant NSCLC. Tango sponsors the trial while Erasca supplies ERAS-0015 at no cost under a mutually non-exclusive agreement.
  • Revolution Medicines (Tango combination context)minorOthers · 5 March 2026Referenced as a partner of Tango Therapeutics running a parallel combination trial with vopimetostat (PRMT5 inhibitor) + daraxonrasib (Revolution Medicines' RAS inhibitor); comparable to Erasca's combination trial with vopimetostat + ERAS-0015.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Erasca competitors and assessment

Company assessment

Emerging players

  • Verastem Oncology: Verastem is developing VS-7375, an oral KRAS G12D inhibitor intended for combination with Erasca's ERAS-0015. Verastem is a focused emerging player in RAS-mutant oncology with overlapping indications in pancreatic and other RAS-mutant tumors.
  • Tango Therapeutics: Tango Therapeutics is both an Erasca combination partner (vopimetostat + ERAS-0015) and an emerging precision oncology peer with synthetic-lethality programs including PRMT5 inhibition. Tangentially competing in the same patient populations via combination strategies.
  • PMV Pharmaceuticals: PMV Pharma is a clinical-stage precision oncology company developing small molecules that reactivate mutant p53 (e.g., PC14586). Comparable as a similarly-sized clinical-stage precision oncology company with a focused mechanism-driven approach.
  • Foghorn Therapeutics: Foghorn Therapeutics is a clinical-stage precision oncology company targeting the chromatin regulatory system, with a pipeline of small molecules. Comparable as a precision oncology peer with multiple programs in development against oncology targets.

Broad incumbents

  • Amgen: Amgen developed and commercializes LUMAKRAS (sotorasib), the first FDA-approved KRAS G12C inhibitor. As a broad incumbent in RAS-targeted oncology, Amgen is a major competitor in commercial positioning and combination strategy.
  • Bristol-Myers Squibb: BMS owns KRAZATI (via Mirati acquisition) and has deep oncology commercial reach, positioning it as a broad incumbent competing with Erasca's RAS/MAPK pipeline. BMS is also a potential strategic acquirer for pan-RAS assets in the same competitive space.

Direct peers

  • Revolution Medicines: Revolution Medicines is Erasca's closest direct competitor, developing RMC-6236 (a pan-RAS(ON) inhibitor) and daraxonrasib (KRAS G12D), and is the comparator in Erasca's own preclinical studies. RevMed and Erasca are currently engaged in active IP/trade-secret litigation over ERAS-0015.
  • Mirati Therapeutics: Mirati developed KRAZATI (adagrasib), a KRAS G12C inhibitor, making it a direct KRAS competitor to Erasca's pan-RAS and KRAS programs. Acquired by Bristol-Myers Squibb in 2024, Mirati's portfolio provides a benchmark for RAS-targeting clinical and commercial execution.
  • Black Diamond Therapeutics: Black Diamond is a clinical-stage precision oncology company developing a pipeline of targeted therapies against oncogenic driver mutations. Comparable in size, modality mix (small molecules), and clinical-stage risk profile to Erasca.
  • Relay Therapeutics: Relay Therapeutics is a clinical-stage precision oncology company developing RLY-4008 (lirafugratinib) and other targeted therapies with a motion-based drug discovery platform. Comparable as a similarly-sized clinical-stage precision oncology peer with pipeline depth and similar burn profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Erasca social profiles

Digital presence

Erasca financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Erasca leadership team

Management profile

Number of profiles

Profiles19 records

Erasca subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Erasca funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Erasca M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Erasca

What does Erasca do?

Erasca is a clinical-stage precision oncology biopharmaceutical company developing a modality-agnostic pipeline of 11 investigational drug programs (small molecules, large molecules, protein degraders) that comprehensively target the RAS/MAPK signaling cascade across three strategies: MAPKlamp upstream/downstream node inhibition, direct RAS targeting, and escape-route targeting. Lead clinical assets ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor) are advancing through Phase 1 trials in RAS-mutant solid tumors.

Is Erasca a public or private company?

Erasca is a public company. It is classified as public and is currently operating.

When was Erasca founded?

Erasca was founded in 2018. It employs 101 to 250 people.

Where is Erasca based?

Erasca is headquartered in San Diego, United States, in the North America region.

How does Erasca make money?

Three revenue lines are on record. No commercial product revenue is the primary driver. The others are public equity financing and licensed pan-RAS molecular glue franchise (ERAS-0015).

Who are Erasca's main competitors?

Emerging players on record are Verastem Oncology, Tango Therapeutics, PMV Pharmaceuticals and Foghorn Therapeutics. Broad incumbents are Amgen and Bristol-Myers Squibb. Direct peers are Revolution Medicines, Mirati Therapeutics, Black Diamond Therapeutics and Relay Therapeutics.

Does Erasca have an API?

No public API is recorded for Erasca.

What industry is Erasca in?

Erasca's product category is Precision Oncology Drug Development. Its primary akta.pro industry code is HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services, with a secondary code of HLAGACAK, Clinical Trial Pharmacy & IMP Management at Site. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewBristol to evaluate navlimetostat in combination with Erasca assetBristol Myers Squibb and Erasca are evaluating navlimetostat combined with Erasca's ERAS-0015 for pancreatic ductal adenocarcinoma. Erasca will supply the pan-RAS molecular glue, while Bristol runs the trial. ERAS-0015 is also in the AURORAS-1 phase 1 trial for RAS-mutant solid tumors.MarketScreenerErasca, Inc. Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with NavlimetostatErasca, Inc. and Bristol Myers Squibb announced a clinical trial collaboration to evaluate ERAS-0015, a pan-RAS molecular glue, with navlimetostat in patients with MTAP-deleted pancreatic ductal adenocarcinoma. Bristol Myers Squibb will sponsor the trial, and Erasca will supply ERAS-0015, with both parties retaining development and commercial rights.TradingViewErasca, Inc. (ERAS) to Evaluate ERAS-0015 With BMS in Pancreatic Cancer TrialErasca and Bristol Myers Squibb entered a clinical trial collaboration to evaluate ERAS-0015 with navlimetostat in MTAP-deleted pancreatic cancer. BMS will sponsor the Phase 1/2 trial, while Erasca supplies the compound, with no financial terms disclosed. Each party retains rights to its compound.Investing.comWhy is Erasca stock sliding today?Erasca stock fell nearly 4.9% in morning trading, pulling back to $14.375 after HC Wainwright materially lowered its per-share loss estimates across a multi-year horizon. Leerink Partners initiated coverage with an Outperform rating and $35 price target, but the negative sentiment from the estimate cuts and a pending insider share sale outweighed the bullish initiation.Simply Wall StErasca (ERAS) Gets Fast Track And Starts New Trial As Undervalued Case Stays AliveErasca received FDA Fast Track status for ERAS-0015 and initiated a Phase 1/2 combination trial. The stock is up 339.55% year-to-date, but the market prices it about 35% below the analyst consensus fair value of $24.11. Planned trials in 2027-2028 could expand its addressable market.PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERASPomerantz LLP is investigating securities fraud claims on behalf of Erasca, Inc. investors. The investigation follows Erasca's October 16, 2026 filing announcing COO Nicholas Chetwyn's termination, which caused the stock to fall 9.95% to $13.39. Investors are advised to contact Pomerantz's Danielle Peyton.Business & FinancialAttention Long-Term Shareholders Of Coastal Financial Corporation (NASDAQ: CCB) Erasca, Inc. (NASDAQ: ERAS) O-I Glass, Inc. (NYSE: OI) And Sprout Social, Inc. (NASDAQ: SPT): Grabar Law Office Is Investigating Claims On Your BehalfGrabar Law Office is investigating potential securities fraud claims against Coastal Financial, Erasca, O-I Glass, and Sprout Social, alleging breaches of fiduciary duty and misleading statements. The claims include a $42.1 million net loss for Coastal and a court ruling that a Sprout Social fraud case survived a motion to dismiss.FinancialContent Business PageAttention Long-Term Shareholders of Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); O-I Glass, Inc. (NYSE: OI); and Sprout Social, Inc. (NASDAQ: SPT): Grabar Law Office is InGrabar Law Office announced investigations into Coastal Financial, Erasca, O-I Glass, and Sprout Social, alleging fiduciary breaches and securities fraud. The claims include undisclosed credit losses, misleading product comparisons, and false statements about sales strategies. A court denied a motion to dismiss the Sprout Social case.